Cipla Ltd
CIPLA
Company Profile
Business description
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Contact
Ganpatrao Kadam Marg
Cipla House, Peninsula Business Park
Lower Parel
MumbaiMH400 013
INDT: +91 2224826000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
47,496
Stocks News & Analysis
stocks
Chart of the Week: Is CSL finally turning the ship around?
The beaten down healthcare giant remains cheap on turnaround potential.
stocks
ASX top pick remains cheap with narrowing brand focus
Shares remain cheap for ASX winemaker as the company narrows focus on high margin brands.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,861.70 | 96.20 | 1.10% |
| CAC 40 | 8,161.83 | 41.60 | -0.51% |
| DAX 40 | 24,195.31 | 237.75 | -0.97% |
| Dow JONES (US) | 49,918.78 | 953.33 | -1.87% |
| FTSE 100 | 10,254.81 | 27.48 | 0.27% |
| HKSE | 24,208.68 | 199.28 | -0.82% |
| NASDAQ | 25,169.50 | 509.32 | -1.98% |
| Nikkei 225 | 64,295.59 | 116.32 | 0.18% |
| NZX 50 Index | 13,182.99 | 70.66 | -0.53% |
| S&P 500 | 7,266.99 | 119.66 | -1.62% |
| S&P/ASX 200 | 8,661.50 | 98.00 | 1.14% |
| SSE Composite Index | 3,964.24 | 28.98 | -0.73% |